Brief: Paratek Awarded Barda Project Bioshield Contract For Nuzyra
18/12/2019 22:28
Dec 18 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK AWARDED BARDA PROJECT BIOSHIELD CONTRACT FOR
NUZYRA®
* PARATEK PHARMACEUTICALS INC - TOTAL AWARD VALUED AT UP TO
$285
MILLION
* PARATEK PHARMACEUTICALS - HHS, ASPR, BARDA AWARDED CO
5-YEAR
CONTRACT TO SUPPORT DEVELOPMENT OF CO'S NUZYRA FOR TREATMENT OF
PULMONARY ANTHRAX
* PARATEK PHARMACEUTICALS - HHS, ASPR, BARDA CONTRACT TO
ALSO
SUPPORT FDA POST-MARKETING REQUIREMENTS ASSOCIATED WITH INITIAL
NUZYRA APPROVAL
* PARATEK PHARMACEUTICALS - HHS, ASPR, BARDA CONTRACT ALSO
HAS
OPTION TO PROCURE UP TO 10,000 TREATMENT COURSES OF NUZYRA FOR
STRATEGIC NATIONAL STOCKPILE
Source text for Eikon: ID:nGNX3yYfC1
Further company coverage: PRTK.O
((Briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million